By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: PROACTIS SA – Press Release (nomination C. Carter and P. Shepherd) 19.12.2025
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Technology > PROACTIS SA – Press Release (nomination C. Carter and P. Shepherd) 19.12.2025
PROACTIS SA – Press Release (nomination C. Carter and P. Shepherd) 19.12.2025
Technology

PROACTIS SA – Press Release (nomination C. Carter and P. Shepherd) 19.12.2025

GlobeNews Wire
Last updated: 19/12/2025 11:39 PM
GlobeNews Wire
Published: 19/12/2025
Share
SHARE

Press Release

Evolution of PROACTIS SA Governance

PARIS, France – (19 December 2025) — Under the terms of the Board of Directors of the company PROACTIS SA (ISIN code: FR0004052561) held on the 18th of December 2025, Mrs. Charlotte CARTER has been appointed as Director in replacement of Mrs. Bonnie MITCHELL, resigning.

Charlotte Carter joined Proactis in 2013. She is Vice President for Product at Proactis, where she leads a high-performing team dedicated to investing in our next generation of software products. She brings over 12 years of experience in the Source-to-Pay software domain, with expertise in procurement, spend control and SaaS and is supported by CIPS certification and executive education from MIT Sloan.

During this same meeting, Mr. Peter SHEPHERD has been appointed as Director in replacement of Mr. Graham DAVIS, resigning.

Peter Shepherd joined Proactis in November 2025 after being CFO at Medical Management Systems LTD. He brings over 20 years of experience in senior financial roles, with strong expertise in strategy, growth management, and financial excellence within international organizations. His experience and leadership will be instrumental in helping Proactis Group continue its evolution.

Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31st, 2026.

As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows:

Member Functions Mandate expiry date
Andrew REARDON Chairman of the Board of Directors
Chief Executive Officer
Annual General Meeting to approve the financial statements for the year ending January 31, 2028
Charlotte CARTER Director Annual General Meeting to approve the financial statements for the year ending January 31, 2030
Peter SHEPHERD Director Annual General Meeting to approve the financial statements for the year ending January 31, 2028
Maria LARSEN Director Annual General Meeting to approve the financial statements for the year ending January 31, 2028

* * * *

Contacts
Tel: +33 (0)1 53 25 55 00
E-mail: investorContact@proactis.com

* * * *

  • PROACTIS SA – Press Release (nomination C. Carter and P. Shepherd) 19.12.2025
Axtria Recognized as Leading AI Service Provider with Minsky Award at Cypher 2025
Apollomics Announces Settlement of Cayman Litigation
Kaleris and Port of Tanjung Pelepas Recognized for Advancement Optimization With 2025 Top Supply Chain Projects Award
RIMAN Honored with iF DESIGN AWARD 2026, Strengthening Its Global Brand Leadership
ACKO’s Grand Traffic Challan Report: Delhi Leads E Challan Fines
TAGGED:19.12.2025AdventureandcarterFR0004052561newsnominationParis:HBWpressproactisreleaseshepherd)
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
Health

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

GlobeNews Wire
GlobeNews Wire
02/03/2026
Medical Device Manufacturers Accelerate R&D and Speed to Market via Live Prototyping
Crossover Markets Announces Record Results
From Kuala Lumpur to Hanoi: Milken Institute’s 2026 Global Opportunity Index Portrays Resiliency and Encouraging Growth Trend in Emerging Southeast Asia
Guangdong aims to shoulder greater responsibilities at the beginning of the 15th Five-Year Plan period
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?